Shoulder Innovations (SI) Q3 2026 Earnings Call Transcript
Shoulder Innovations reported Q3 2026 net revenue of $16.2M, up 38% YoY, with gross margin at 78.5%. The company raised full-year revenue guidance to $68M-$70M, up 44%-48% YoY. They launched new products, including the InSet Go glenoid implant, and saw strong surgeon adoption and procedural growth. The company expects continued momentum and plans to expand its commercial team.
How this was made

The 30-second read
Why it matters
The key tradable items are the FY2026 net revenue guidance raise, Q3 revenue and gross margin strength, and early commercialization progress for next-generation implants, all framed against orthopedic seasonality and CMS reimbursement developments.
Market read
A company-specific earnings call with a concrete guidance raise and multiple operating metrics can drive near-term positioning and expectations for 2026 demand and margins.
What to watch
The transcript notes more pronounced seasonality among core surgeons and incremental cost initiatives expected to contribute beginning in 2027, which could affect margin trajectory beyond 2026.
Background
The company discusses Q3 performance, surgeon adoption and utilization, and commercialization of InSet Go and N-22 products, alongside favorable CMS final rulings.
Ticker impact
Shoulder Innovations raised full-year 2026 net revenue guidance to $68M-$70M and reported Q3 revenue up 38% YoY with 78.5% gross margin.
Likely upward bias as traders price in higher 2026 revenue growth and margin durability, while monitoring adoption and CMS-related demand.
The article contains a fresh guidance update with specific ranges and multiple operating datapoints (revenue, gross margin, implant volume) plus product commercialization milestones and favorable CMS rulings.
Market effects
Reinforces demand and reimbursement tailwinds for shoulder arthroplasty device makers following favorable CMS rulings.
Primarily US-focused commercial execution and surgeon adoption dynamics.
Limited direct global impact; US reimbursement and orthopedic procedure volumes are the main driver.
Counterpoint
Raised guidance may already reflect expected seasonality normalization, so upside could be capped if surgeon funnel conversion or implant utilization slows in Q4.
Key entities
- companyShoulder Innovations
Orthopedic implant company reporting Q3 results and raising FY2026 net revenue guidance; launching InSet Go and N-22 products.
- regulatorCMS (Centers for Medicare & Medicaid Services)
CMS final rulings related to shoulder arthroplasty referenced as favorable for the company’s market.
- productInSet Go
Next-generation glenoid implant launched with reduced surgical steps; surgeons report positive response.
- productN-22 humeral head
FDA-cleared N-22 humeral head launched to extend the N-22 line for metal hypersensitivity into anatomic procedures.


